Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

https://ift.tt/7ilxwD9

Dupixent^® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine

from Sanofi - Aventis Groupe https://ift.tt/CkX3hPo
via IFTTT